An Allogeneic TCR-T Cell Therapy for COVID-19

Time: 1:00 pm
day: Day One


  • A fully allogeneic TCR-T therapy for COVID-19 was created using Poseida’s core nonviral technologies: piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, and Booster Molecule
  • Three lead TCRs, each recognizing a different immunodominant HLA-A*02:01 restricted epitope in three separate SARS-CoV-2 proteins, were developed for optimal functional avidity
  • TCR-T products were produced and effector function was evaluated